AMIX Stock — Autonomix Medical, Inc. Common Stock

Autonomix Medical, Inc. Common Stock (AMIX)

Updated October 16, 2026.

AMIX is a Stock. Total return is -99.9% over the past 2.7 years, 160.3 points behind SPY at 60.4%.

Autonomix Medical is a development-stage medical device company focused on catheter-based systems that use microchip-enabled sensing to detect neural signals from within the vascular system. The company is developing its technology platform for applications in pancreatic cancer treatment and chronic pain management, as well as conditions related to hypertension, cardiovascular disease, and other nerve-related disorders. The company does not currently have an established distribution schedule.

AMIX performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 2.7 years, 160.3 points behind SPY at 60.4%. Over the past year its total return — price change plus distributions reinvested — is -87.8%. Its deepest 1-year drawdown was 88.6%.

AMIX key facts

Asset type

Stock

Asset class

Equity

Inception date

01/29/2024

Distribution frequency

None

Last close

$2.85 (as of 2026-10-16)

Market cap

$5,576,024

Average volume

30236.0

Beta

-0.943

Payout ratio

0.0%

EPS

$-39.67

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AMIX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 88.6%.

Who may consider AMIX — and who may not

It is a weaker fit for investors who need monthly cash flow (AMIX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AMIX

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions